GOG-240 — Improved Survival with Bevacizumab in Advanced Cervical Cancer

Phase 3 · 2014 · Cervical Cancer

Design

Randomized phase III trial with a 2-by-2 factorial design evaluating the addition of bevacizumab to chemotherapy (cisplatin/paclitaxel or topotecan/paclitaxel) in recurrent, persistent, or metastatic cervical cancer.

Population

Women with recurrent, persistent, or metastatic cervical cancer not curable with standard treatment.

Primary Endpoint

Overall survival

Key Result

Adding bevacizumab to chemotherapy increased median overall survival to 17.0 vs 13.3 months (HR for death 0.71, 98% CI 0.54-0.95; P=0.004) with higher response rates (48% vs 36%).

Guideline Impact

Led to FDA approval and guideline adoption of bevacizumab plus chemotherapy for advanced cervical cancer